The association of Wnt-signalling and EMT markers with clinical characteristics in women with endometrial cancer

Frontiers in Oncology

Oncology

Tomaž Büdefeld¹  Uroš Potočnik²  Živa Ledinek³  Damjan Sisinger³  Marko Hojnik³  Monika Sobočan⁴  Jure Knez⁴ 

[1] Center for Human Molecular Genetics and Pharmacogenomics, Faculty of Medicine, University of Maribor, Maribor, Slovenia;Center for Human Molecular Genetics and Pharmacogenomics, Faculty of Medicine, University of Maribor, Maribor, Slovenia;Laboratory for Biochemistry, Molecular Biology and Genomics, University of Maribor, Maribor, Slovenia;Department for Science and Research, University Medical Centre Maribor, Maribor, Slovenia;Department of Pathology, University Medical Centre Maribor, Maribor, Slovenia;Divison for Gynaecology and Perinatology, University Medical Centre Maribor, Maribor, Slovenia;Department of Gynaecology and Obstetrics, Faculty of Medicine University of Maribor, Maribor, Slovenia;

关键词: Wnt pathway;    EMT - epithelial to mesenchymal transformation;    endometrial cancer (EC);    β-catenin (B-catenin);    DKK1;    E-cadherin;    N-cadherin;   

DOI  :  10.3389/fonc.2023.1013463

 received in 2022-08-07, accepted in 2023-02-20,  发布年份 2023

来源: Frontiers

【 摘 要 】

Endometrial cancer is the most common gynecologic malignancy in the developed world. Risk stratification and treatment approaches are changing due to better understanding of tumor biology. Upregulated Wnt signaling plays an important role in cancer initiation and progression with promising potential for development of specific Wnt inhibitor therapy. One of the ways in which Wnt signaling contributes to progression of cancer, is by activating epithelial-to-mesenchymal transition (EMT) in tumor cells, causing the expression of mesenchymal markers, and enabling tumor cells to dissociate and migrate. This study analyzed the expression of Wnt signaling and EMT markers in endometrial cancer. Wnt signaling and EMT markers were significantly correlated with hormone receptors status in EC, but not with other clinico-pathological characteristics. Expression of Wnt antagonist, Dkk1 was significantly different between the ESGO-ESTRO-ESP patient risk assessment categories using integrated molecular risk assessment.

【 授权许可】

Unknown   
Copyright © 2023 Ledinek, Sobočan, Sisinger, Hojnik, Büdefeld, Potočnik and Knez